Express News | Shapuaisi: Obtained the Drug Registration Certificate for Sildenafil Citrate Orally Disintegrating Tablets

BreakingsMay 25 16:38

Zhejiang Shapuaisi Pharmaceutical Terminates 528 Million-Yuan Plan to Buy Shanghai Tianlun Hospital Owner

MT NewswiresMay 7 19:21

Shapuaisi Terminates Acquisition with 24x Premium Amid Continuous Losses and Goodwill Impairment Pressures | Express Report

① Supor terminated the acquisition of Shanghai Qinli for 5.28 billion yuan; the net assets of the target company are 20.97 million yuan, with an assessed value increase rate of 24 times; ② The Shanghai Stock Exchange issued a letter inquiring about the reasonableness of the valuation, and the China Securities Investor Service Center pointed out doubts regarding the annual average growth rate of the target company's net profit. After multiple delays, the company did not disclose its response to the inquiry; ③ The company continues to incur losses, and the two hospitals acquired earlier have both failed to meet their performance commitments, resulting in pressure on operations and financial liquidity.

cls.cnMay 6 22:00

Shapaisi: Shapaisi\'s First Quarter Report for 2026

SZSIApr 30 00:00 · Announcements

Shapaisi First Quarter Report for 2026

SZSIApr 30 00:00 · Announcements

Shapuaisi (603168.SH) reported a net loss of 26.104 million yuan in the first quarter.

Gelonghui reported on April 29 that Supor (603168.SH) released its Q1 2026 financial report, showing that the company achieved operating revenue of 98.5227 million yuan in the first quarter, representing a year-on-year decline of 3.15%; net profit attributable to shareholders of -26.104 million yuan; and non-recurring net profit attributable to shareholders of 185,600 yuan, marking a year-on-year increase of 116.21%.

Gelonghui FinanceApr 29 18:26